Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBITDA Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBITDA Margin for 4 consecutive years, with 155.47% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 7321.0% to 155.47% in Q3 2025 year-over-year; TTM through Sep 2025 was 150.61%, a 6453.0% decrease, with the full-year FY2024 number at 93.9%, up 21173.0% from a year prior.
  • EBITDA Margin was 155.47% for Q3 2025 at bioAffinity Technologies, up from 194.65% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 171.34% in Q2 2022 to a low of 166806.19% in Q1 2023.
  • A 4-year average of 23663.72% and a median of 147.42% in 2025 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -907473bps in 2023, then soared 16672697bps in 2024.
  • bioAffinity Technologies' EBITDA Margin stood at 69213.21% in 2022, then surged by 100bps to 98.32% in 2023, then tumbled by -34bps to 131.53% in 2024, then fell by -18bps to 155.47% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EBITDA Margin are 155.47% (Q3 2025), 194.65% (Q2 2025), and 139.37% (Q1 2025).